Alterman A I, Droba M, Antelo R E, Cornish J W, Sweeney K K, Parikh G A, O'Brien C P
VA Medical Center, Philadelphia, PA.
Drug Alcohol Depend. 1992 Oct;31(1):19-29. doi: 10.1016/0376-8716(92)90004-v.
The effectiveness of amantadine hydrochloride was evaluated in a double-blind placebo controlled drug trial. The subjects were 42 cocaine dependent men enrolled in a day hospital program. Twenty-one patients were prescribed 100 mg/bid of amantadine to be taken over 10.5 days and 21 were prescribed an equivalent amount of placebo. The primary outcome measures were the Addiction Severity Index at 1 month after study entry and urines during the drug trial (end of weeks 1 and 2) and 1 month after study entry. Urines obtained at the end of the drug trial (2 weeks) indicated that the subjects receiving amantadine (93%) were more likely (P = 0.040) to be free of cocaine than the placebo (60%) subjects. Urine toxicology data at 1-month follow-up again indicated that more of the amantadine subjects (83%) were free of cocaine than the placebo (53%) subjects (p = 0.049); although no differences were found in self-reports of cocaine or other substance use in the past 30 days. The urine findings provided preliminary indication that amantadine may have some effectiveness in reducing cocaine use in cocaine dependent patients.
在一项双盲安慰剂对照药物试验中评估了盐酸金刚烷胺的有效性。受试者为42名参加日间医院项目的可卡因依赖男性。21名患者被开了100毫克/每日两次的金刚烷胺，服用10.5天，21名患者被开了等量的安慰剂。主要结局指标为研究入组后1个月的成瘾严重程度指数以及药物试验期间（第1周和第2周结束时）和研究入组后1个月的尿液检测结果。在药物试验结束时（2周）采集的尿液表明，服用金刚烷胺的受试者（93%）比服用安慰剂的受试者（60%）更有可能（P = 0.040）戒除可卡因。1个月随访时的尿液毒理学数据再次表明，戒除可卡因的金刚烷胺组受试者（83%）比安慰剂组受试者（53%）更多（p = 0.049）；尽管在过去30天内可卡因或其他物质使用的自我报告中未发现差异。尿液检测结果初步表明，金刚烷胺在减少可卡因依赖患者的可卡因使用方面可能有一定效果。
